PCOS is increasingly affecting young women. Discover the key risk factors, symptoms, and management strategies to protect your health and well-being.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Ya7CcSh
via IFT...
Zydus Lifesciences gets warning letter from USFDA for its Jarod injectable unit
Zydus Lifesciences received a warning letter from the USFDA regarding its injectables manufacturing facility at Jarod, following an inspection in April 2024. The letter cites violations of cGMP regulations. Zydus must respond within 15 days and take remedial action. The warning limits new product launches, impacting business growth in the US market.
from...
Zydus Lifesciences gets USFDA nod to market Scopolamine transdermal system
Zydus Lifesciences Ltd has received USFDA approval to market its Scopolamine transdermal system, which helps prevent nausea and vomiting under various conditions, including after surgery and due to motion sickness. The product, with a dosage of 1 mg/3 days, will be manufactured in Ahmedabad.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/kSlFUcB
via...
7 protein-packed dinners for healthy weight loss
These 7 high-protein dinner recipes, including grilled chicken salad, baked salmon, and quinoa bowls, are designed to help with weight loss by providing satisfying, nutrient-rich meals that support your goals.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Wb5dFV0
via IFT...
Want to purify your blood? Try these 6 foods
Discover 6 natural foods that can help purify your blood, removing toxins and improving circulation. From beetroot to turmeric, these everyday ingredients support detoxification and enhance overall health.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/SuOZPnU
via IFT...
Biocon settles with Janssen to commercialise biosimilar products in Europe, Canada, Japan
Biocon Biologics has entered into a settlement and licence agreement with Janssen Biotech Inc, Janssen Sciences Ireland, and Johnson & Johnson to launch Bmab 1200, a biosimilar to Stelara, in Europe, the UK, Canada, and Japan. This deal resolves patent disputes and secures future market entry, pending regulatory approvals.
from Healthcare/Biotech-Industry-Economic...
Indian pharma exporters feel pain on Bangladesh crisis
The political unrest and violence in Bangladesh are posing significant challenges for Indian pharmaceutical exporters, leading to stranded funds and concerns over financial stability. This situation threatens to impact medicine availability and healthcare services in Bangladesh. Despite the market's growth potential, many Indian companies are now hesitant...
Hillhouse bids highest to buy healthcare BPO GeBBS from Chrys Cap for $870 mn
GeBBS Healthcare Solutions, a Los Angeles-based healthcare BPO firm, is nearing acquisition by Hillhouse Investment, which has offered about $870 million. The final decision is expected in two weeks as ChrysCapital holds another round of negotiations. The acquisition will potentially see industry veterans Gautam Barai and Gautam Narayan at the helm.
from...
Sloth fever outbreak: Key facts on the deadly virus and should you be worried?
The Oropouche virus, also known as "sloth fever," is spreading in South America and the Caribbean. Transmitted by midges and mosquitoes, it causes symptoms similar to dengue and Zika, with no vaccine or specific treatment available.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Y175rKt
via IFT...
Fairfax, Bain look to buy Gujarat's API Company Farmson
Canadian billionaire Prem Watsa's Fairfax Group and Bain Capital are in competition for a buyout of Farmson Basic Drugs, a leading API maker in India valued at ₹4,000 crore. Founded in 1969, Farmson is a major paracetamol manufacturer with a revenue of ₹1,750 crore in FY24. The company's concentrated focus on paracetamol production is a strength, but...
Bharat Biotech launches oral cholera vaccine Hillchol after positive phase 3 trial
Bharat Biotech unveiled Hillchol, a new single-strain oral cholera vaccine, developed with Hilleman Laboratories. Addressing the high global demand for cholera vaccines, the company can produce up to 200 million doses annually. Phase 3 trials validated its safety and effectiveness. The vaccine is administered orally to individuals over one year old.
from...
India develops indigenous Monkeypox RT-PCR testing kit, gets CDSCO approval
India has successfully developed its own indigenous RT-PCR testing kit to combat Monkeypox. The kit, created by Siemens Healthineers, has received manufacturing approval from the Central Drugs Standard Control Organisation (CDSCO).
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/jkEF31M
via IFT...
More fixed-dose combo drugs may enter ban list
The Indian government recently banned 156 fixed-dose combination drugs, citing health risks. An expert committee found these combinations lacking therapeutic justification. More FDCs are under review and could face imminent bans as part of ongoing evaluations to ensure public safety.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ZW1Qoh2
via...
Alembic Pharma gets USFDA nod for generic drug
Alembic Pharmaceuticals has been granted final approval from the USFDA for its generic Betamethasone Valerate Foam, intended to treat moderate-to-severe psoriasis of the scalp. This medication is equivalent to Luxiq Foam by Norvium Bioscience. Alembic’s shares ended 0.97% lower at Rs 1,089.90 on the BSE.
from Healthcare/Biotech-Industry-Economic Times...
TB testing technology developed by ICMR's regional centre allows tests at Rs 35
ICMR has introduced a new CRISPR-based technology for detecting tuberculosis at a low cost. Capable of testing 1,500 samples in a short period, this system aims to address limitations of existing methods. ICMR plans to commercialise this technology, offering technical support and seeking partner organisations.
from Healthcare/Biotech-Industry-Economic...
Pharma companies seek more time to implement revised norms on manufacturing practices
Schedule M of the Drugs and Cosmetics Rules, 1945 prescribes the good manufacturing practices (GMP) for pharmaceutical products, such as a prompt product recall system for products known or suspected to be defective. Pharma lobby groups have written to the health minister, seeking an extension of the December 2024 deadline to December 2026, citing...
India aims to lead next industrial revolution with biomanufacturing policy: DBT
India introduced the BioE3 policy to tackle challenges related to food, energy, and climate. Approved by the Union Cabinet, the policy focuses on enhancing innovation in biomanufacturing, covering everything from medicines to bio-plastics. The initiative is expected to create job opportunities and promote sustainable development. The policy aligns...
Danfoss India confident of doubling sales by 2025, company president says
Danfoss India, a subsidiary of the Denmark-based Danfoss Group, is experiencing significant growth in the Indian market and aims to double its sales by 2025. The Indian market is the fastest-growing region for Danfoss, driven by increased opportunities in energy efficiency and electrification. The company reported a 10.6% EBITDA margin for the first...
USFDA pulls up Eugia for manufacturing lapses, data accuracy at Hyderabad plant
The US Food and Drug Administration (USFDA) has issued a warning letter to Eugia Pharma Specialities, a subsidiary of Aurobindo Pharma, citing significant manufacturing issues at its Telangana plant. The USFDA's inspection from January 22 to February 2, 2024, revealed problems including inaccurate production and process simulation data, falsified environmental...
Revoke 18% GST on health and life insurance premium: TMC to Nirmala Sitharaman
TMC leader Derek O'Brien has urged Finance Minister Nirmala Sitharaman to remove the 18% GST on health and life insurance premiums at the upcoming GST Council meeting. He argues that the tax is a burden on the middle class and may discourage people from buying or renewing insurance. O'Brien cited a February 2024 report from the Standing Committee on...
Zydus Lifesciences acquires 50% stake in Sterling Biotech
Zydus Lifesciences entered a joint venture with Perfect Day by acquiring a 50% stake in Sterling Biotech. The collaboration aims to build a manufacturing facility for animal-free protein products, addressing global demand. This venture marks Zydus' entry into the biotech sector, focusing on health and nutrition solutions for lactose-intolerant consumers...
Zydus Lifesciences to acquire 50 pc stake in Sterling Biotech from Perfect Day
Zydus Lifesciences announced an agreement with Perfect Day Inc to acquire a 50 per cent stake in Sterling Biotech. The partnership aims to establish a manufacturing facility for animal-free protein production. This move signifies Zydus' expansion into specialized biotech products catering to health and nutrition markets, particularly for those preferring...
Govt bans 156 fixed-dose combo drugs over risks
FDCs are medicines that combine two or more drugs into a single dosage. The union health and family welfare ministry on Thursday issued a gazette notification, prohibiting manufacture, sale and distribution of these medicines based on the recommendation of an expert panel that evaluated 324 FDCs.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/98mzx2L
via...
B'desh upheaval takes a toll on medical tourism in India
The number of Bangladeshi patients visiting India for medical treatment has plummeted by up to 50% due to political unrest in Bangladesh. This downturn has impacted revenues for Indian hospitals. Pharma exports to Bangladesh are also at risk, as the country sources 30% of its pharmaceutical ingredients and raw materials from India, potentially affecting...
ICMR-led study estimates 10-year risk of developing heart disease in adults in India
An ICMR-led study has found that unemployed adults in India have a significantly higher risk of developing heart disease over the next decade. The research analyzed nearly 4,500 adults aged 40-69 years, showing that men and urban residents have higher risks. High blood sugar and obesity also contribute to increased cardiovascular risks.
from Healthcare/Biotech-Industry-Economic...
Alkem arm ties up with Exactech for knee, hip replacement implants
Alkem Laboratories has announced a partnership through its subsidiary, Alkem MedTech, with US-based Exactech Inc to manufacture and market large joint implants in India. The deal grants Alkem MedTech marketing rights for Exactech's implant brands, including Truliant, Optetrak, and Logic Fit.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/dIxBQVv
via...
USFDA flags Telangana unit of Aurobindo Pharma arm
The letter, issued on August 15, was later made public by the USFDA, which stated that there was failure to ensure the accuracy of data in records for both production and process simulations, i.e. media fills. Media fill is a microbiological test to help prevent contamination during drug production.
from Healthcare/Biotech-Industry-Economic Times...
Scheme to bolster medical device industry to roll out soon: Pharma Secretary
The Department of Pharmaceuticals will launch a new scheme within a month to strengthen the domestic medical device industry, according to Secretary Arunish Chawla. The initiative, developed after extensive consultations, aims to reduce import reliance and promote self-reliance. The scheme has secured in-principle approval from the Finance Ministry.
from...
Indoco Remedies gets USFDA nod to market Lofexidine tablets with 180 days exclusivity
Indoco Remedies Ltd was granted approval from the USFDA to sell its generic Lofexidine tablets, used for opioid withdrawal. This approval includes 180 days of market exclusivity. The company plans an immediate US launch, manufacturing the product in Goa. Expected sales are estimated at USD 15.59 million, with significant growth anticipated.
from Healthcare/Biotech-Industry-Economic...
Mpox vaccine coming soon, says Covishield manufacturer SII's CEO Adar Poonawalla
Adar Poonawalla of the Serum Institute of India announced that the company was developing a Mpox vaccine, with results expected within a year. The government issued isolation guidelines for suspected cases, and the NIV in Pune tested samples. Experts highlighted concerns about the new CLADE 1B lineage but did not foresee a lockdown.
from Healthcare/Biotech-Industry-Economic...
Ipca Labs expects its US generics sales to touch $200 million soon
Ipca Laboratories, after resolving regulatory hurdles and integrating Unichem, is set to re-enter the US generics market aiming for $200 million in revenue within 12-18 months. The focus is on commercializing existing products after an import ban by the US FDA was lifted. Unichem has shown profits following these efforts.
from Healthcare/Biotech-Industry-Economic...
Serum Institute says working to develop Monkeypox vaccine
The World Health Organisation on August 14 declared the Mpox outbreak a public health emergency of international concern. The move came after a sudden increase in cases was recorded in parts of Africa. In India, around 30 Mpox cases have been detected since 2022. The most recent case in the country was reported in March 2024.
from Healthcare/Biotech-Industry-Economic...
Bloated every morning? Try these home remedies for gas relief
Waking up with a bloated stomach can ruin your day. Morning gas, often caused by diet and stress, can be eased with natural remedies like ginger tea, warm lemon water, or fennel seeds for quick relief.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/j4UAYb0
via IFT...
Granules India gets USFDA nod for generic Glycopyrrolate oral solution
Granules Pharmaceuticals Inc, a subsidiary of Granules India, has received approval from the USFDA for a generic Glycopyrrolate oral solution meant for pediatric patients with neurological conditions associated with drooling. The medication is bioequivalent to Cuvposa Oral Solution by Merz Pharmaceuticals and has a strength of 1mg/5mL.
from Healthcare/Biotech-Industry-Economic...
Operation buyout: KKR, TPG, and other PE firms eye purchase of India's largest cardiac stent maker SMT
Morgan Stanley PE Asia and Samara Capital collectively own 49% of the company while Kotak Pre IPO Opportunities Fund holds 6%. The Kotadias, the company's promoters, own the remaining 45%.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/13F4CcZ
via IFT...
Health ministry approves 25% enhancement in security deployment at central hospitals
Amid protests following a trainee doctor's alleged rape and murder in Kolkata, the Health Ministry increased security at Union hospitals by 25%. Officials noted that existing state laws already protect healthcare workers. A new committee will examine hospital security and facilities. Authorities urged striking doctors to resume work to avoid affecting...
Aurobindo Pharma to commercialise China plant in third quarter of FY25: CFO
Aurobindo Pharma's China facility is set to start production in the next quarter, with full-scale output expected in the next fiscal year. The company plans to roll out small volumes in November-December, ramping up in January-March. Chief Financial Officer Santhanam Subramanian anticipates commercialisation in Q3 FY25 and volume production in FY26....
Indian govt needs to trim citizens' waist size for the sake of economy
India's Economic Survey 2023-24 warned that increasing obesity rates could hinder the country's economic potential. Experts urged the government to promote healthier lifestyles through better diet, physical activity, and monitoring of health parameters. Emphasizing waist circumference and BMI, they suggested that addressing obesity is crucial to reaping...
PM Modi monitoring Mpox status; meeting takes stock of preparedness
Prime Minister Narendra Modi has been monitoring the Mpox situation with no current cases in the country. A high-level meeting assessed the risk of a major outbreak as low. Experts recommended screening travelers and using existing COVID-19 infrastructure to contain potential cases. Transparent reporting and international collaboration were emphasized.
from...
Baba Ramdev criticises 'toxic' allopathy medicines that 'killed' millions of Indians
Baba Ramdev voiced his opposition to allopathy, claiming millions in India have died from synthetic drugs. At a press conference, he highlighted the need for medical autonomy and a swadeshi revolution through Patanjali to achieve economic and medical freedom. He accused foreign pharmaceutical companies of creating dependency on harmful medications...
Ipca launches new topical therapy against diabetic foot ulcer
Ipca Laboratories introduced Diulcus, a topical gel designed to treat diabetic foot ulcers, priced at Rs 1365 per pack. The gel is based on repurposed beta blocker Esmolol. Approved after clinical trials, the product showed promising ulcer closure rates, with Ipca targeting a substantial market share within three years.
from Healthcare/Biotech-Industry-Economic...
Domestic pharmaceutical retail market grows 11 per cent in July
The domestic pharmaceutical retail market saw an impressive 11% growth in July, attributed to increased sales of anti-infectives and pain relief due to rising flu and viral infections. Antibiotic Augmentin led sales at Rs 72 crore and topped the charts. Overall market valued at Rs 2,22,906 crore, showing 7 per cent growth in June. Sun Pharma maintained...
Aurobindo Pharma's Eugia Unit-3 gets warning letter from USFDA, shares fall
Aurobindo Pharma's subsidiary Eugia Pharma Specialities received a warning letter from the USFDA concerning its formulations manufacturing unit in Telangana. This followed an earlier inspection that resulted in an 'Official Action Indicated' status. Aurobindo affirmed that current US supplies are unaffected and emphasized their commitment to enhancing...
AstraZeneca gets $107 mln Pfizer verdict overturned in US cancer drug patent fight
On Wednesday, U.S. District Judge Matthew Kennelly invalidated Pfizer’s patents related to the cancer drug Nerlynx, overturning a jury's $107.5 million award against AstraZeneca. Pfizer had claimed AstraZeneca's Tagrisso infringed these patents. Judge Kennelly's ruling found the patents lacked sufficient written descriptions and were not reproducible...
Aurobindo may take its injectable unit public
Aurobindo Pharma is revisiting plans to sell a strategic stake in its injectable unit, Eugia Pharma Specialities, focusing on an IPO. Previously hampered by valuation issues with private equity, the process faces new hurdles due to USFDA observations. Eugia aims to reach $600 million in revenue this fiscal year. Regulatory issues at Unit-3 remain a...
Nishkala Healthcare acquires Navi Mumbai's Suasth Hospital under IBC process
Nishkala Healthcare acquired Suasth Healthcare Foundation's 400-bed hospital in Navi Mumbai for Rs 189 crore under IBC. Funded through Rs 73 crore in equity and bank loans, the purchase follows the hospital's admission into insolvency. Nishkala aims to enhance the hospital’s value and expand into medical education.
from Healthcare/Biotech-Industry-Economic...
Alembic gets USFDA nod for generic medication
Alembic Pharmaceuticals announced approval from the USFDA to market Dabigatran Etexilate Capsules (110 mg) for deep vein thrombosis prophylaxis, equivalent to Pradaxa Capsules. The company now has 211 ANDA approvals. Shares closed 3.17% lower at Rs 1,076 on the BSE.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Ugt7MJ5
via IFT...
Southern states witness majority heart transplants owing to more donations
Southern states in India lead in heart transplantation as per Notto data. Tamil Nadu topped the list at 70 transplants, followed by Karnataka, Maharashtra, Gujarat, and Telangana. South India receives more heart donations due to increased deceased donations. India recorded 1,099 heart donations in 2023, with Telangana leading at 252, followed by Tamil...
Biocon arm's growth formula: US rollouts & debt reduction
Biocon Biologics planned to introduce six new biosimilar products in the US in the next two years, subject to regulatory approval. They emphasized debt reduction and cost optimization, having paid $175 million out of $335 million for a key acquisition. Their revenue increased 3% in Q1FY25 due to gains in the biosimilars market.
from Healthcare/Biotech-Industry-Economic...
SSUHS signs MoU with Novo Nordisk Foundation
Srimanta Sankaradeva University of Health Sciences and Novo Nordisk Foundation signed an MoU to enhance Assam's health sector. The deal aims to improve nursing education, including an Education Innovation Unit and Simulation Lab. The partnership provides initial financial support of Rs 6 crore and promises further collaboration to improve nursing education...
Revenue of domestic API firms to see 7-8 pc increase by 2029: Report
The revenue of domestic active pharmaceutical ingredients (API) producers in India is projected to grow by 7-8% annually by 2029, according to a report by ICRA. The rating agency estimates that revenues will increase from USD 13-14 billion in 2023, driven by the pharmaceutical formulations industry and factors like an aging population, rising chronic...
Dr Reddy's gets establishment inspection report from USFDA for Visakhapatnam units
Dr Reddy's Laboratories Ltd has obtained an Establishment Inspection Report from the USFDA for its Duvvada units, now classified as Voluntary Action Indicated. The units underwent an inspection from May 8 to May 17, 2024, which led to a Form 483 with observations. Dr Reddy’s planned to resolve the issues within the given time.
from Healthcare/Biotech-Industry-Economic...
As monsoon takes hold, anti-infective, respiratory drugs' demand surges
Monsoon led to a surge in demand for respiratory, anti-infective, and anti-malarial products. The respiratory market saw a notable increase in Poractant Alfa usage. Anti-malaria medicines experienced significant growth, driven by seasonal patterns. Core therapeutic areas like cardiac, respiratory, and gastro contributed to the overall market growth.
from...
What not to drink: 7 beverages that can worsen fatty liver
If you're looking to manage or avoid fatty liver, it's important to be cautious about your drink choices. Here are seven drinks that are generally considered worse for fatty liver:
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/egYRT6t
via IFT...
At over 10 cr, India’s diabetic population is surging, yet the country lags behind in prescribing new medicines
Priya Rao experienced confusion and worry after fainting and receiving different diabetic medications from two doctors. The first doctor followed global guidelines, while the second used Indian ones, stabilizing her condition. The case underscores different diabetic treatment protocols and the importance of tailored patient care in India.
from Healthcare/Biotech-Industry-Economic...
Explore lesser-known Indian nuts: Chilgoza, Chiraunji & their benefits
India boasts a rich tradition of nuts in cooking and medicine. While almonds and cashews are common, lesser-known nuts like chilgoza and chiraunji offer unique flavors and significant health benefits.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/FpzmhJD
via IFT...
Hospital chain Medanta lines up Rs 1,200 crore for Mumbai entry
Global Health, operator of Medanta hospitals, is set to build a 500-bed super specialty hospital in Mumbai with an investment of ₹1,200 crore. The project, funded equally by debt and internal accruals, will be completed in 3-4 years. Medanta recently acquired the land in Oshiwara through a public auction.
from Healthcare/Biotech-Industry-Economic...
India eases drug approval process, waives local trials for advanced therapies
In a major policy shift, the Indian government has waived local clinical trial requirements for drugs and vaccines approved by major international regulators (US, UK, Japan, Australia, Canada, EU). This move, aimed at expediting access to advanced therapies like CAR T-cell therapy and Sacituzumab govitecan, still ensures post-marketing surveillance...
Biotech giant Amgen plans to open to technology & innovation centre in Hyderabad
US biotech giant Amgen announced plans to open a new technology and innovation site in Hyderabad, India. The site will be located in HITEC City and will occupy six floors of the RMZ Spire Tower. It is expected to be operational in Q4 2024 and has the potential to accommodate up to 3,000 people.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/dRoODCN
via...
Fortis Healthcare to buy out PE funds from diagnostics arm Agilus
Fortis Healthcare has acquired a 34% stake in Agilus Diagnostics from private equity firms Jacob Ballas and IFC. This transaction valued Agilus at around ₹5,000 crore and increased Fortis's holding from 57% to 91%. Agilus operates 413 laboratories and faced expansion challenges due to investors' reluctance and rising competition from new-age online...
Bajaj could make a difference in healthcare space
The Bajaj group's move into the hospital industry promises to influence the Indian healthcare sector. Private hospitals have shown growth and investor interest has risen post-pandemic. Bajaj plans to establish hospitals in metropolitan areas but will face significant hurdles such as high costs and a lack of medical professionals.
from Healthcare/Biotech-Industry-Economic...
India waives clinical trial requirement for drugs approved in developed markets
India has waived clinical trial requirements for new drugs with significant therapeutic advances that have been approved in the US, UK, Japan, Australia, Canada, or the EU. The Central Drugs Standard Control Organisation (CDSCO) stated that this move aims to speed up drug availability, especially for rare diseases, pandemics, and special defence needs.
from...
India's Fortis Healthcare chairman Ravi Rajagopal resigns
Ravi Rajagopal has resigned as chairman of Fortis Healthcare, effective Sept. 30, due to increased commitments in the U.K. and other regions. He will also step down from the Corporate Social Responsibility Committee. Rajagopal became chairman in June 2018 when Fortis was dealing with significant challenges, and he found his tenure personally fulfilling.
from...
BHU study on Covaxin had serious methodological flaws as per ICMR: Prataprao Jadhav
The Indian Council of Medical Research (ICMR) reviewed a study on the long-term safety of Covaxin in adults and adolescents, conducted by Banaras Hindu University, and found significant methodological flaws. Minister of State for Health Prataprao Jadhav informed the Rajya Sabha that the study lacked a control group of unvaccinated individuals, making...
Pharma industry urges govt for stable drug pricing policy
The Organisation of Pharmaceutical Producers of India (OPPI) has called for a stable and predictable drug pricing policy, urging the government to avoid using Para 19 of the Drug Pricing Control Order (DPCO), which allows significant price reductions in the public interest.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/muJ9vQw
via...
Hamara Hospital! Bajaj plans a healthcare ride
The Bajaj Group, worth ₹1.46 lakh crore, initiated steps to venture into the healthcare industry by setting up hospitals in metros. Overseen by Nirav Bajaj, the project will be housed in a new company, with phased investments based on milestones. This marks the group's first major diversification since Rahul Bajaj's death in 2022.
from Healthcare/Biotech-Industry-Economic...
New data reveals why patients from the US and UK are flocking to India for organ transplants
In 2023, India conducted 1,851 organ transplants for foreign nationals, accounting for nearly 10% of all transplants. The majority of these transplants took place in Delhi, Rajasthan, and West Bengal. Foreign patients primarily seek living donor transplants due to lower costs and strict vetting protocols. Deceased donations are rare and usually reserved...
Sun Pharma's hair loss drug in the cross hairs in US
Leqselvi is used for the treatment of alopecia areata, an autoimmune disease that leads to hair loss, and was approved by the US Food and Drug Administration (USFDA) last week. Sun Pharma has been making preparations for months to launch the drug in July, but an injunction motion by the American drugmaker lncyte Corporation in the US District Court...
Bharat Biotech credited ICMR, NIV as Covaxin co-inventors after missing them initially: Government
Responding to Trinamool Congress member Sougata Roy, who had asked whether the government took any punitive action against the company for not mentioning the names of ICMR and NIV in the patent application, the Union Health and Family Welfare Minister gave a detailed reply. There was a joint Memorandum of Understanding (MoU) between ICMR, NIV and Bharat...
Sanofi gets drug regulator nod to market RSV therapy in India
French drugmaker Sanofi announced on Thursday that it has received approval from India's Central Drugs Standard Control Organization (CDSCO) to market its novel therapy, Beyfortus, in India. The therapy is aimed at protecting newborns and infants from respiratory syncytial virus (RSV).
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/l0YUjf7
via...